Details of Disease

General Information of Disease (ID: DISCFBRD)

Disease Name Neurological disorder
Disease Class 6B60: Dissociative neurological symptom disorder
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DISCFBRD: Neurological disorder
ICD Code
ICD-11
ICD-11: 6B60
Expand ICD-9
338,338.2,410,782.3,780
Disease Identifiers
MONDO ID
MONDO_0005071
MESH ID
D009422
UMLS CUI
C0027765
MedGen ID
14336
SNOMED CT ID
118940003

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 4 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
GM-CSF DMVJALH Approved NA [1]
Heroin diacetylmorphine DMDBWHY Approved Small molecular drug [2]
Meticillin DMIKHN0 Approved Small molecular drug [3]
Glypromate DM0OX31 Phase 4 NA [4]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 15 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
AM-111 DM4E9PK Phase 3 NA [5]
Coprexa DMA0WEK Phase 3 Small molecular drug [6]
IDAZOXAN HYDROCHLORIDE DMSP0X8 Phase 3 Small molecular drug [7]
ERYTHRITOL DMATPN3 Phase 2/3 Small molecular drug [8]
DT-1687 DMU2GP4 Phase 2 NA [9]
LX-6171 DMCVCZ6 Phase 2 NA [10]
PYM-50028 DMLQK6E Phase 2 NA [11]
SUVN-502 DMQD753 Phase 2 Small molecular drug [12]
TPI-926 DM6NWJI Phase 2 NA [13]
TRAXOPRODIL MESYLATE DM1ZQEN Phase 2 Small molecular drug [14]
Lu-AF11167 DM97V4W Phase 1 NA [15]
NBQX DMPHZI5 Phase 1 Small molecular drug [16]
OPC-14117 DMZWFKQ Phase 1 Small molecular drug [17]
R4996 DMSKHIC Phase 1 NA [18]
TEV-56192 DM41ZNM Phase 1 Antibody [19]
------------------------------------------------------------------------------------
⏷ Show the Full List of 15 Drug(s)
This Disease is Treated as An Indication in 18 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
LUBELUZOLE DMFGMD9 Discontinued in Preregistration Small molecular drug [20]
Aloxistatin DMGW07M Discontinued in Phase 3 Small molecular drug [21]
HER-801 DMSHB46 Discontinued in Phase 2 NA [22]
RC-552 DMW2RBZ Discontinued in Phase 2 NA [23]
SIPATRIGINE DMMQ4GC Discontinued in Phase 2 Small molecular drug [24]
TAK-218 DM7S69Q Discontinued in Phase 2 NA [25]
Tetramethylpyrazine DMC0WNB Discontinued in Phase 2 Small molecular drug [26]
CGP-37849 DMOULQ4 Discontinued in Phase 1 Small molecular drug [27]
Licostinel DMMWCU3 Discontinued in Phase 1 Small molecular drug [28]
Lu-AA38466 DMGUX5Y Discontinued in Phase 1 NA [29]
MX-4509 DMC4RK7 Discontinued in Phase 1 Small molecular drug [30]
NSD-644 DMNL9DS Discontinued in Phase 1 NA [31]
U-104067F DMC94D2 Discontinued in Phase 1 Small molecular drug [32]
CLR-901 DM6LX8X Terminated NA [34]
L-698532 DMO9HM7 Terminated Small molecular drug [35]
LY-367385 DM98POQ Terminated Small molecular drug [36]
SDZ-SER-082 DMXHW91 Terminated Small molecular drug [37]
Seridopidine DMTBWU1 Terminated Small molecular drug [38]
------------------------------------------------------------------------------------
⏷ Show the Full List of 18 Drug(s)
This Disease is Treated as An Indication in 2 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
BIIR-777 DM2JOXF Preclinical NA [33]
TEV-46000 DMYJA85 Preclinical NA [19]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 36 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
A-558693 DMN320E Investigative NA [39]
ACPC DMAZLWR Investigative NA [40]
ARX-212 DMB7BZE Investigative NA [41]
BQCA DMSGIXK Investigative Small molecular drug [42]
CL-301 DMW3RLB Investigative NA [43]
CM-182 DM82NQG Investigative NA [41]
CN-2097 DMJA8I4 Investigative NA [44]
CogniXan DMKFJG5 Investigative NA [41]
CP-809101 DM3M1LA Investigative Small molecular drug [45]
CPG23NEUR DMX7D2G Investigative NA [41]
FUB-130 DMCLSE0 Investigative Small molecular drug [46]
HBN-1 DMLNHZJ Investigative NA [41]
HBN-2 DM5VDU2 Investigative NA [47]
HG-1336 DMCY6GL Investigative NA [41]
JWB-1-84-1 DMXZ9RF Investigative NA [48]
KI-0801 DM3A7EL Investigative NA [41]
Lixte-1.2 DMG82HZ Investigative NA [41]
NK-2210 DM192OD Investigative NA [41]
PA-1637 DMUH203 Investigative NA [49]
PRX-12205 DML7TZ5 Investigative NA [41]
PRX-12239 DMTZPPK Investigative NA [41]
PRX-12247 DMJ2T1M Investigative NA [41]
PRX-12255 DM2V9VT Investigative NA [41]
PRX-12256 DM6EGU9 Investigative NA [41]
PRX-12261 DMD5JBD Investigative NA [41]
PRX-12266 DMX1NA0 Investigative NA [41]
PT-00311 DMB2SN7 Investigative NA [41]
Recombinant botulinum toxin DMA6VCG Investigative NA [48]
RTI-4229-982 DMG6TOA Investigative NA [50]
SEM-606 DMDIZUT Investigative NA [49]
SUVN-501 DMT8PKC Investigative NA [51]
SUVN-507 DM2UMK8 Investigative NA [51]
SY-300 DMU9X3N Investigative NA [41]
TA-111 DM472WM Investigative NA [41]
TZ-111 DM7KKLM Investigative NA [41]
UBP-551 DMTP31P Investigative NA [41]
------------------------------------------------------------------------------------
⏷ Show the Full List of 36 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4942).
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Alpha-conotoxins. Int J Biochem Cell Biol. 2000 Oct;32(10):1017-28.
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021881)
5 ClinicalTrials.gov (NCT02235272) Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation. U.S. National Institutes of Health.
6 Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82.
7 ClinicalTrials.gov (NCT00294944) The Effectiveness of Idazoxan in Treating TRD. U.S. National Institutes of Health.
8 ClinicalTrials.gov (NCT01062633) Effect of Erythritol and Xylitol on Dental Caries Prevention in Children. U.S. National Institutes of Health.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 292).
10 ClinicalTrials.gov (NCT00691808) Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment. U.S. National Institutes of Health.
11 PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J. 2008 Jul;22(7):2488-97.
12 Clinical pipeline report, company report or official report of Suven Life Sciences.
13 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021731)
14 ClinicalTrials.gov (NCT00163059) The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD. U.S. National Institutes of Health.
15 ClinicalTrials.gov (NCT02199431) Study to Evaluate the Effect of a Known and Marketed Product, Itraconazole (Mycosis Treatment) on Lu AF11167 Entering the Body and Subsequently Elimination. The Studyis a Drug-drug Interaction Study in Healthy Volunteers.. U.S. National Institutes of Health.
16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4264).
17 ClinicalTrials.gov (NCT00002148) Parallel Group, Placebo-Controlled, Tolerability, Safety, and Efficacy Study of OPC-14117 in HIV Dementia. U.S. National Institutes of Health.
18 Clinical pipeline report, company report or official report of Roche.
19 Clinical pipeline report, company report or official report of Teva Pharmaceutical
20 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005388)
21 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002441)
22 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038058)
23 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011811)
24 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003904)
25 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009120)
26 Determination of tetramethylpyrazine in animal serum and cerebrospinal fluid by high performance liquid chromatography. Se Pu. 2000 Jan;18(1):46-8.
27 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4154).
28 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003616)
29 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029333)
30 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020680)
31 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027571)
32 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006788)
33 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025224)
34 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023986)
35 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006620)
36 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1379).
37 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 195).
38 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011877)
39 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2336).
40 1-Aminocyclopropane carboxylic acid (ACPC) prevents mu and delta opioid tolerance. Life Sci. 1994;55(18):1393-8.
41 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
42 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5436).
43 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 969).
44 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
45 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 8).
46 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1260).
47 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 309).
48 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467).
49 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
50 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293).
51 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 11).